April 14, 2018
Baseline HbA1c and, to some extent, diabetes duration were the primary drivers of degree of treatment response to liraglutide.
Treatment response in patients with type 2 diabetes (T2D) receiving liraglutide was correlated with diabetes duration and glycated hemoglobin (HbA1c) levels, according to a study published in Acta Diabetologica.
Medical records from participants in the ReaL observational study (ClinicalTrials.gov identifier:
NCT02255266) with T2D receiving liraglutide for the first time were evaluated and compared between groups who either did (n=577) or did not (n=748) achieve an HbA1c reduction of ≥1.0 percentage point. Information from the records included fasting plasma glucose, body weight, body mass index, diabetes duration, presence of diabetes complications, and diabetes treatments.